Status:

ACTIVE_NOT_RECRUITING

Early Detection of Patients at Risk of Developing Anthracycline Cardiotoxicity With TEP/CT -FDG

Lead Sponsor:

Assistance Publique - Hôpitaux de Paris

Conditions:

Lymphoma, Non-Hodgkin

Lymphoma, Hodgkin

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

Management of patients with lymphoma is based on the administration of a chemotherapy containing anthracyclines (ATC), and allows cure rates of 65% to 80% at 5 years. The administration of ATCs can le...

Detailed Description

This is a study that evaluates the sensitivity of the cardiac uptake of 18F-FDG measured on D28 +/- 7 days, D42 +/- 7 days ou D56 + 4 days of the administration of ATCs to identify at 1 year the patie...

Eligibility Criteria

Inclusion

  • Patients of at least 18 years of age, treated as part of an initial extension assessment (staging) of a lymphoma (Hodgkin's or non-Hodgkin's)
  • Treatment with a chemotherapy protocol containing Anthracyclines (ABVD protocol, enhanced BEACOPP, R CHOP, CHOP, CHOEP, EPOCH, ACVBP)
  • Signed informed consent
  • Affiliation to a social security system (AME excepted)

Exclusion

  • FEVG\<53%
  • Cardiological symptomatic patient (Dyspnea, angina, palpitations, syncope, left ventricular insufficiency, right ventricular insufficiency, overall heart failure)
  • Patient for whom PET/CT invalidates the presence of lymphoma (Hodgkin's or non-Hodgkin's)Uncontrolled blood pressure (AP) (systolic AP \> 140 mm Hg and/or diastolic AP \> 90 mmHg)
  • Myocardial infarction in the 3 months prior to inclusion
  • Heart failure in the 3 months prior to inclusion
  • Severe symptomatic or asymptomatic mitral valvulopathy
  • Symptomatic or asymptomatic tight aortic stenosis
  • Atrial Fibrillation
  • Pregnant or lactating woman
  • Hypersensitivity to 18F-FDG
  • Patient under guardianship or curatorship
  • Patient under State Medical Aid

Key Trial Info

Start Date :

April 1 2022

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

March 17 2026

Estimated Enrollment :

128 Patients enrolled

Trial Details

Trial ID

NCT04892667

Start Date

April 1 2022

End Date

March 17 2026

Last Update

August 13 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Cardiology department

Paris, France, 75012

Early Detection of Patients at Risk of Developing Anthracycline Cardiotoxicity With TEP/CT -FDG | DecenTrialz